+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incretin modulators, a new perspective in diabetes mellitus treatment



Incretin modulators, a new perspective in diabetes mellitus treatment



Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 116(2): 630-634



The study was designed to present the modern therapy used for the treatment of type 2 diabetes mellitus (T2DM). Diabetes mellitus and the pharmacological and the pharmacokinetic characteristics of the incretins and of the incretin modulators are presented. Diabetes mellitus is a chronic metabolic disorder, which is considered to be a major health issue all over the world. World Health Organization indicates that world-wide almost 3 million deaths per year are caused by diabetes and 1,5 million new cases are diagnosed annually, T2DM representing approximately 90-95% of the diagnosed cases. This form of diabetes mellitus is characterized by several path physiological defects including insulin resistance at peripheral target tissues, excess hepatic glucose production and progressive pancreatic beta cell dysfunction. The newest direction in the treatment of T2DM mellitus is the incretin modulators. The incretins (GLP-1--glucagon-like-peptide-1 and GIP--glucose-dependent insulin tropic peptide), are natural hormones that contribute to glucose homeostasis by acting on the pancreas, gastrointestinal tract, muscle and brain tissue. After secretion, GLP-1 and GIP are immediately metabolized by dipeptidyl peptidase IV enzyme (DPP IV), which limits their therapeutic use. In order to achieve optimal glycemic control, by using the therapeutic effects of incretins, research has been directed to the development of synthetic analogues of GLP-1 resistant to DPP IV enzyme inactivation and DPP IV inhibitors.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053810379

Download citation: RISBibTeXText

PMID: 23077965


Related references

Application of Incretin to Treatment of Diabetes Mellitus. Nihon Naika Gakkai Zasshi 97(4): 827-835, 2008

Treatment of type 2 diabetes mellitus and the incretin system. South Dakota Medicine 60(5): 197, 199, 2007

Incretin related agents for treatment of diabetes mellitus. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 98(4): 809-816, 2009

Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV. Vnitrni Lekarstvi 53(9): 1005-1009, 2007

Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2. Medizinische Monatsschrift für Pharmazeuten 29(3): 86-89, 2006

Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus. Acta Clinica Belgica 63(2): 81-85, 2008

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clinical Therapeutics 28(5): 652-665, 2006

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus. Peptides 100: 108-113, 2018

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus. Peptides 100: 108-113, 2018

Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh Medical Journal 18(1): 113-124, 2009

Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus. Deutsche Medizinische Wochenschrift 132(11): 571-574, 2007

Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinologica 31(2): 133-147, 2006

Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism 1(3): 329-341, 2006

Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin. Vnitrni Lekarstvi 53(10): 1109-1113, 2007

New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clinical and Experimental Nephrology 17(1): 10-15, 2013